Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
Holding SANA?
Track your performance easily
SANA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.76 - $12.00
Previous Close$2.89
Volume1.88M
Average Volume (3M)1.37M
Market Cap
$645.25M
Enterprise Value$542.32M
Total Cash (Recent Filing)$199.01M
Total Debt (Recent Filing)$96.08M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 13, 2025EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding223,268,889
10 Day Avg. Volume1,778,220
30 Day Avg. Volume1,371,686
Standard Deviation0.26
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$11.67Price Target Upside310.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sana Biotechnology News
PremiumCompany Announcements
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results
PremiumCompany Announcements
Sana Biotechnology Announces Leadership and CFO TransitionBulls Say, Bears Say
Bulls Say
Financial StabilitySana Biotechnology has extended its cash runway into 2026, providing more financial stability for ongoing projects.
Strategic Development FocusSana Biotechnology is prioritizing the development of SC291 in B-cell mediated autoimmune diseases and the type 1 diabetes program, indicating a strategic shift to a potentially untapped market opportunity.
Technological PotentialSana's hypoimmune platform is believed to be capable of producing pancreatic islet cells that evade the immune system and produce insulin, offering potential for long-term value creation and future growth.
Bears Say
Financial PerformanceSana reported a Q3 loss of $60MM, indicating financial challenges.
Pipeline ChallengesThe company has pushed back the initial proof of concept data release for its pancreatic islet cell program, indicating potential delays.
Program De-prioritizationSana is halting further development of SC291 in blood cancers and will seek a partner to advance that portion.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.75 and its highest was $12.00 in the past 12 months.
What is Sana Biotechnology’s market cap?
Currently, no data Available
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Mar 13, 2025 which is in 112 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 08, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.007.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -$0.24.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 223,268,890 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Among the largest hedge funds holding Sana Biotechnology’s share is Flagship Pioneering Inc.. It holds Sana Biotechnology’s shares valued at 137M.
---
Sana Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.67 (310.92% Upside)
$11.67 (310.92% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.24%
12-Months-Change
Fundamentals
Return on Equity
-92.90%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
---
SANA Stock 12 Month Forecast
Average Price Target
$11.67
▲(310.92% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
BioMarin Pharmaceutical
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-27.99%
reiterated a buy rating 15 days ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -27.99% per trade.
---